AU5458500A - Regulation of systemic immune responses utilizing cytokines and antigens - Google Patents

Regulation of systemic immune responses utilizing cytokines and antigens

Info

Publication number
AU5458500A
AU5458500A AU54585/00A AU5458500A AU5458500A AU 5458500 A AU5458500 A AU 5458500A AU 54585/00 A AU54585/00 A AU 54585/00A AU 5458500 A AU5458500 A AU 5458500A AU 5458500 A AU5458500 A AU 5458500A
Authority
AU
Australia
Prior art keywords
antigens
regulation
immune responses
systemic immune
responses utilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54585/00A
Inventor
Glenn Dranoff
Steve Hardy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Genesys Inc
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of AU5458500A publication Critical patent/AU5458500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
AU54585/00A 1999-06-02 2000-06-02 Regulation of systemic immune responses utilizing cytokines and antigens Abandoned AU5458500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32470799A 1999-06-02 1999-06-02
US09324707 1999-06-02
PCT/US2000/015190 WO2000072686A1 (en) 1999-06-02 2000-06-02 Regulation of systemic immune responses utilizing cytokines and antigens

Publications (1)

Publication Number Publication Date
AU5458500A true AU5458500A (en) 2000-12-18

Family

ID=23264740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54585/00A Abandoned AU5458500A (en) 1999-06-02 2000-06-02 Regulation of systemic immune responses utilizing cytokines and antigens

Country Status (2)

Country Link
AU (1) AU5458500A (en)
WO (1) WO2000072686A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355661A2 (en) * 2001-01-31 2003-10-29 Mologen Forschungs-, Entwicklungs- und Vertriebs GmbH Tumor vaccine
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7674456B2 (en) 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
US9107863B2 (en) 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention
AU2007241023B2 (en) 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
WO2008013989A2 (en) 2006-07-27 2008-01-31 Cell Genesys, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
JP5247729B2 (en) 2007-03-02 2013-07-24 セルル ゲネスイス，インコーポレイテッド Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8425897B2 (en) 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
WO2011136828A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
WO2017189281A1 (en) 2016-04-27 2017-11-02 The Regents Of The University Of Michigan C3d cellular and acellular vaccines for the prevention and treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5693531A (en) * 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
US5710037A (en) * 1994-06-10 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Retroviral vector particles
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors

Also Published As

Publication number Publication date
WO2000072686A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
IL122467A0 (en) The regulation of systemic immune responses utilising cytokines and antigens
AU5458500A (en) Regulation of systemic immune responses utilizing cytokines and antigens
AU2395895A (en) Melanoma antigens
AU3146301A (en) Adjustable staircase and method of assembling the same
AU4518196A (en) Adjuvant-incorporated cellular antigens: conjugation and methods
AU678954B2 (en) Belt adjusting device and single facer
AU4139801A (en) Controlled delivery of antigens
GB9927332D0 (en) Novel antibody and uses thereof
AU6941698A (en) Anti-cancer vaccine
AU2247095A (en) Cellular immune response-specific antigens and uses therefor
AU3933500A (en) Methods for skewing the balance between th1 and th2 immune responses
AU6771998A (en) Identification of the progression elevated gene-3 and uses thereof
AU2003204353A1 (en) Methods and compositions for enhancing immune response and for the production of in vitro mabs
AU4014700A (en) Tuberculosis antigens and methods of use therefor
AU5294993A (en) Epidermal surface antigen and uses thereof
AU2539697A (en) Anti-idiotypic antibody vaccines
AU3755999A (en) Proteins that direct the secretion of virulence proteins and vaccines comprisingthem
AU2001266845A1 (en) Modulation of immune response and methods based thereon
AUPP363498A0 (en) Antigens and their detection
AU2502300A (en) Micromachined device and method of forming the micromachined device
AU5851296A (en) Malaria peptides and vaccines
AU2001276581A1 (en) Compositions for inducing self-specific anti-ige antibodies and uses thereof
AU2001271033A1 (en) Means of assaying immune function
AU7585998A (en) Controlling immune response to specific antigens
AU6084598A (en) Antibiotic-ligand conjugates and methods of use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase